Linked Data API

Show Search Form

Search Results

100885
star this property registered interest false more like this
star this property date less than 2014-10-24more like thismore than 2014-10-24
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Asthma: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211885 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2014-10-29more like thismore than 2014-10-29
star this property answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-29T17:12:29.113Zmore like thisremove minimum value filter
star this property question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property previous answer version
25123
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4026
star this property label Biography information for Liz Kendall more like this
224735
star this property registered interest false more like this
star this property date less than 2015-03-03more like thismore than 2015-03-03
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Clinical Commissioning Groups: Cumbria more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20. more like this
star this property tabling member constituency Copeland more like this
star this property tabling member printed
Mr Jamie Reed more like this
star this property uin 226114 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2015-03-06more like thismore than 2015-03-06
star this property answer text <p>Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Allocation £000</p></td><td><p>Per capita £</p></td></tr><tr><td><p>2013/14</p></td><td><p><del class="ministerial">692,122</del></p><p><ins class="ministerial">663,133</ins></p></td><td><p><del class="ministerial">1,330</del></p><p><ins class="ministerial">1,274</ins></p></td></tr><tr><td><p>2014/15</p></td><td><p>677,324</p></td><td><p>1,299</p></td></tr><tr><td><p>2015/16</p></td><td><p>685,654</p></td><td><p>1,313</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>These figures exclude running cost and Better Care Fund allocations.</p><p> </p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2015-03-06T14:39:07.327Zmore like thismore than 2015-03-06T14:39:07.327Z
star this property question first ministerially corrected
less than 2015-03-19T18:02:16.817Zmore like thismore than 2015-03-19T18:02:16.817Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property previous answer version
48371
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1503
star this property label Biography information for Mr Jamie Reed more like this
431742
star this property registered interest false more like this
star this property date less than 2015-11-23more like thismore than 2015-11-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Mental Health Services: Per Capita Costs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much NHS England spent per head on mental health in each year since 2008. more like this
star this property tabling member constituency Central Suffolk and North Ipswich more like this
star this property tabling member printed
Dr Poulter more like this
star this property uin 17404 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2015-11-26more like thismore than 2015-11-26
star this property answer text <p>NHS England was formed in April 2013.</p><br /><p>The table below shows actual expenditure by clinical commissioning groups (CCGs) on mental health in 2013/14 and 2014/15 and forecast spend in 2015/16. This does not include spending on mental health services directly commissioned by NHS England.</p><p>Total actual expenditure by on mental health by CCGs across all providers for 2013/14 and 2014/15 and the total forecast expenditure for 2015/16</p><br /><table><tbody><tr><td><p>2013/14 actual spend (£ <ins class="ministerial">billion </ins><del class="ministerial">million</del>)</p></td><td><p>2014/15 actual spend (£ <ins class="ministerial">billion</ins><del class="ministerial">million</del>)</p></td><td><p>2015/16 forecast spend (£ <ins class="ministerial">billion </ins><del class="ministerial">million</del>)</p></td></tr><tr><td><p>9.6</p></td><td><p>10.1</p></td><td><p>10.6</p></td></tr></tbody></table><br /><p><em>Source:</em> NHS England</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2015-11-26T16:25:03.7Zmore like thismore than 2015-11-26T16:25:03.7Z
star this property question first ministerially corrected
less than 2015-12-02T14:16:07.33Zmore like thismore than 2015-12-02T14:16:07.33Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property previous answer version
32352
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
3932
star this property label Biography information for Dr Dan Poulter more like this
522126
star this property registered interest false more like this
star this property date less than 2016-05-26more like thismore than 2016-05-26
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Human Papillomavirus: Vaccination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 38833 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2016-06-07more like thismore than 2016-06-07
star this property answer text <p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins> <del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p> </p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.</p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2016-06-07T10:57:37.313Zmore like thismore than 2016-06-07T10:57:37.313Z
star this property question first ministerially corrected
less than 2016-06-13T10:14:27.603Zmore like thismore than 2016-06-13T10:14:27.603Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property previous answer version
2228
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
star this property label Biography information for Andrew Gwynne more like this
100716
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Disability Aids more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will publish the Risk Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211709 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN
211707 more like this
211708 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:24.0967252Zmore like thismore than 2014-10-30T16:13:24.0967252Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
star this property label Biography information for Andrew Gwynne more like this
100717
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Disability Aids more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will publish the Impact Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211710 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN
211707 more like this
211708 more like this
211709 more like this
star this property question first answered
less than 2014-10-30T16:13:24.2061433Zmore like thismore than 2014-10-30T16:13:24.2061433Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
star this property label Biography information for Andrew Gwynne more like this
100718
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Disability Aids more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, when he plans to publish the next annual report on Research and Development Work Relating to Assistive Technology. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211707 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN
211708 more like this
211709 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:23.9161629Zmore like thismore than 2014-10-30T16:13:23.9161629Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
star this property label Biography information for Andrew Gwynne more like this
100719
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Disability Aids more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, when he expects the next annual report on Research and Development Work Relating to Assistive Technology to be laid before parliament. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211708 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property grouped question UIN
211707 more like this
211709 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:24.0029324Zmore like thismore than 2014-10-30T16:13:24.0029324Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
star this property label Biography information for Andrew Gwynne more like this
100720
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Osteoporosis: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211731 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins (colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin (Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-30T16:09:20.4432894Zmore like thismore than 2014-10-30T16:09:20.4432894Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4026
star this property label Biography information for Liz Kendall more like this
100724
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
unstar this property hansard heading Motor Neurone Disease: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much has been spent on the prescription of drugs for the treatment of motor neurone disease in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211727 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2014-10-30more like thismore than 2014-10-30
star this property answer text <p>Information on National Health Service expenditure on drugs for the treatment of motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Riluzole is the only drug defined in the British National Formulary as being used for the treatment of motor neurone disease</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p> </p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since a drug could be prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which it may have been prescribed. The information provided may therefore include costs from the prescribing of the drug for conditions other than for motor neurone disease.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman remove filter
star this property question first answered
less than 2014-10-30T16:04:31.3067599Zmore like thismore than 2014-10-30T16:04:31.3067599Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4026
star this property label Biography information for Liz Kendall more like this